REFERENCES
1. Lu J, Xia Q, Zhou Q. How to make insulin-producing pancreatic β cells for diabetes treatment. Sci China Life Sci 2017;60:239-48.
2. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018;391:541-51.
3. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. SEARCH for Diabetes in Youth Study. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. N Engl J Med 2017;376:1419-29.
4. Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med 2017;376:1407-18.
5. Lee C, Sung NJ, Lim HS, Lee JH. Emergency Department Visits Can Be Reduced by Having a Regular Doctor for Adults with Diabetes Mellitus: Secondary Analysis of 2013 Korea Health Panel Data. J Korean Med Sci 2017;32:1921-30.
6. Kim MS, Lee DY. Urinary Glucose Screening for Early Detection of Asymptomatic Type 2 Diabetes in Jeonbuk Province Korean Schoolchildren. J Korean Med Sci 2017;32:985-91.
7. Shin WY, Lee T, Jeon DH, Kim HC. Diabetes, Frequency of Exercise, and Mortality Over 12 Years: Analysis of the National Health Insurance Service-Health Screening (NHIS-HEALS) Database. J Korean Med Sci 2018;33:e60.
8. Cho S, Shin JY, Kim HJ, et al. Chasms in Achievement of Recommended Diabetes Care among Geographic Regions in Korea. J Korean Med Sci 2019;34:e190.
9. Lloyd CE, Nouwen A, Sartorius N, et al. Prevalence and correlates of depressive disorders in people with Type 2 diabetes: results from the International Prevalence and Treatment of Diabetes and Depression (INTERPRET-DD) study, a collaborative study carried out in 14 countries. Diabet Med 2018;35:760-9.
10. Wang JL, Qin Z, Wang ZJ, et al. New predictors of in-stent restenosis in patients withdiabetes mellitusundergoing percutaneous coronary intervention with drug-eluting stent. J Geriatr Cardiol 2018;15:137-45.
11. Jakobsen GS, Småstuen MC, Sandbu R, et al. Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities. JAMA 2018;319:291-301.
12. Hu CS, Han YL, Ge JB, et al. A novel management program for hypertension. Cardiovasc Diagn Ther 2015;5:316-22.
13. Hu C, Tkebuchava T, Hu D. Managing acute myocardial infarction in China. Eur Heart J 2019;40:1179-81.
14. Hu CS, Wu QH, Hu DY, Tkebuchava T. Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come. Chronic Dis Transl Med 2019;5:75-88.
15. Hu CS. A comprehensive strategy for managing arrhythmogenic right ventricular cardiomyopathy. Turk Kardiyol Dern Ars 2020;48:88-95.
16. Hu CS. Intervention of RT-ABCDEF for cancer. Croat Med J 2019;60:55-7.
17. Hu CS, Tkebuchava T. SARS and its treatment strategies. Asian Pac J Trop Med 2019;12:95-7.
18. Reaven PD, Emanuele NV, Wiitala WL, et al. VADT Investigators. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up. N Engl J Med 2019;380:2215-24.
19. Schauer PR, Bhatt DL, Kirwan JP, et al. STAMPEDE Investigators. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med 2017;376:641-51.
20. Gong L, Li R, Ren W, et al. The FOXO1 Gene-Obesity Interaction Increases the Risk of Type 2 Diabetes Mellitus in a Chinese Han Population. J Korean Med Sci 2017;32:264-71.
21. Selvin E, Wang D, Lee AK, Bergenstal RM, Coresh J. Identifying Trends in Undiagnosed Diabetes in U.S. Adults by Using a Confirmatory Definition: A Cross-sectional Study. Ann Intern Med 2017;167:769-76.
22. Esteghamati A, Khandan A, Momeni A, et al. Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease. Ir J Med Sci 2017;186: 785-94.
23. Liu B, Ye X, Zhao G, Jin L, Shi J. Association of RAGE with acute ischemic stroke prognosis in type 2 diabetes. Ir J Med Sci 2021;190:625-30.
24. Argun D, Argun F, Borku Uysal B. Evaluation of salusin-alpha and salusin-beta levels in patients with type 2 diabetes mellitus and determination of the impact of severity of hyperglycemia on salusin levels. Ir J Med Sci 2021;190:1403-11.
25. Fangel MV, Nielsen PB, Kristensen JK, et al. Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. Am J Med 2020;133:e269-79.
26. Johansen MY, MacDonald CS, Hansen KB, et al. Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial. JAMA 2017;318:637-46.
27. Hu C. Grants supporting research in China. Eur Heart J 2018;39:2342-4.
28. Hu CS, Tkebuchava T. SEEDi1.0-3.0 strategies for major noncommunicable diseases in China. J Integr Med 2017;15:265-9.
29. Miller KA, Siscovick DS, Sheppard L, et al. Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med 2007;356: 447-58.
30. Coogan PF, White LF, Jerrett M, et al. Air pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles. Circulation 2012;125:767-72.
31. Yang BY, Qian ZM, Li S, et al. Ambient air pollution in relation to diabetes and glucose-homoeostasis markers in China: a cross-sectional study with findings from the 33 Communities Chinese Health Study. Lancet Planet Health 2018;2: e64-73.
32. Bowe B, Xie Y, Li T, Yan Y, Xian H, Al-Aly Z. The 2016 global and national burden of diabetes mellitus attributable to PM(25) air pollution. Lancet Planet Health 2018;2:e301-12.
33. Zhang S, Mwiberi S, Pickford R, et al. Longitudinal associations between ambient air pollution and insulin sensitivity: results from the KORA cohort study. Lancet Planet Health 2021;5:e39-49.
34. Liu L, Wang F, Lu H, et al. Effects of Noise Exposure on Systemic and Tissue-Level Markers of Glucose Homeostasis and Insulin Resistance in Male Mice. Environ Health Perspect 2016;124:1390-8.
35. Hu CS, Tkebuchava T. E-noise: An increasingly relevant health risk. J Integr Med 2019;17:311-4.
36. Osborne MT, Naddaf N, Abohashem S, et al. A neurobiological link between transportation noise exposure and metabolic disease in humans. Psychoneuroendocrinology 2021;131:105331.
37. Eriksson JG, Kajantie E, Lampl M, Osmond C. Trajectories of body mass index amongst children who develop type 2 diabetes as adults. J Intern Med 2015;278: 219-26.
38. Elmasry A, Lindberg E, Berne C, et al. Sleep-disordered breathing and glucose metabolism in hypertensive men: a population-based study. J Intern Med 2001; 249:153-61.
39. Pan KY, Xu W, Mangialasche F, Fratiglioni L, Wang HX. Work-related psychosocial stress and the risk of type 2 diabetes in later life. J Intern Med 2017;281:601-10.
40. Giovannucci EL, Rezende LFM, Lee DH. Muscle-strengthening activities and risk of cardiovascular disease, type 2 diabetes, cancer and mortality: A review of prospective cohort studies. J Intern Med 2021;290:789-805.
41. Wang Y, Lee DC, Brellenthin AG, et al. Leisure-Time Running Reduces the Risk of Incident Type 2 Diabetes. Am J Med 2019;132:1225-32.
42. Carlsson S, Andersson T, Araghi M, et al. Smokeless tobacco (snus) is associated with an increased risk of type 2 diabetes: results from five pooled cohorts. J Intern Med 2017;281:398-406.
43. Shi L, Brunius C, Johansson I, et al. Plasma metabolite biomarkers of boiled and filtered coffee intake and their association with type 2 diabetes risk. J Intern Med 2020;287:405-21.
44. Martin WP, Sharif F, Flaherty G. Lifestyle risk factors for cardiovascular disease and diabetic risk in a sedentary occupational group: the Galway taxi driver study. Ir J Med Sci 2016;185:403-12.
45. Liu G, Li Y, Hu Y, et al. Influence of Lifestyle on Incident Cardiovascular Disease and Mortality in Patients With Diabetes Mellitus. J Am Coll Cardiol 2018;71:2867-76.
46. Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. J Am Coll Cardiol 2017;70:883-93.
47. Unick JL, Beavers D, Bond DS, et al. Look AHEAD Research Group. The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med 2013;126:236-42;242.e1-2.
48. Grabovac I, Smith L, Stefanac S, et al. Health Care Providers’ Advice on Lifestyle Modification in the US Population: Results from the NHANES 2011-2016. Am J Med 2019;132: 489-97.e1.
49. Song G, Chen C, Zhang J, Chang L, Zhu D, Wang X. Association of traditional Chinese exercises with glycemic responses in people with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. J Sport Health Sci 2018;7:442-52.
50. McMacken M, Shah S. A plant-based diet for the prevention and treatment of type 2diabetes. J Geriatr Cardiol 2017;14:342-54.
51. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med 2018;379:1540-50.
52. Pittas AG, Dawson-Hughes B, Sheehan P, et al. D2d Research Group. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med 2019;381: 520-30.
53. Hu CS, Tkebuchava T. New “P” in Medical Model. Chin Med J (Engl) 2016;129: 492-3.
54. Gazzaruso C, Coppola A, Pujia A, et al. Erectile dysfunction as a predictor of asymptomatic coronary artery disease in elderly men with type 2diabetes. J Geriatr Cardiol 2016;13:552-6.
55. Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes. J Am Coll Cardiol 2019;74: 2982-94.
56. Rutter MK, Wahid ST, McComb JM, Marshall SM. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 2002;40:56-61.
57. Low Wang CC, Blomster JI, Heizer G, et al. EUCLID Trial Executive Committee and Investigators. Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. J Am Coll Cardiol 2018;72:3274-84.
58. Laiteerapong N, Cooper JM, Skandari MR, et al. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med 2018;168:170-8.
59. Husain M, Birkenfeld AL, Donsmark M, et al. PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019;381:841-51.
60. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Ellipse Trial Investigators. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med 2019;381:637-46.
61. Marso SP, Baeres FMM, Bain SC, et al. LEADER Trial Investigators. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. J Am Coll Cardiol 2020;75:1128-41.
62. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017;377:839-48.
63. Kosiborod M, Lam CSP, Kohsaka S, et al. CVD-REAL Investigators and Study Group. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol 2018;71:2628-39.
64. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-57.
65. Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019;380:2295-306.
66. Wanner C, Inzucchi SE, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016;375:323-34.
67. Sharma A, Ofstad AP, Ahmad T, et al. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. JACC Heart Fail 2021;9:568-77.
68. Bilgin S, Kurtkulagi O, Duman TT, et al. Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study. Ir J Med Sci 2021;1-6.
69. Marso SP, McGuire DK, Zinman B, et al. DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med 2017;377: 723-32.
70. Schmedt N, Enders D, Walker J, Garbe E, Douros A. Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study. Am J Med 2021;134: 606-13.e6.
71. Ferraro RA, Nass CM, Dudum R, Blumenthal RS, Sarkar S. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes. Am J Med 2019;132:1027-31.
72. Newman JD, Vani AK, Aleman JO, Weintraub HS, Berger JS, Schwartzbard AZ. The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review. J Am Coll Cardiol 2018;72:1856-69.
73. Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380:347-57.
74. Filippatos G, Bakris GL, Pitt B, et al. FIDELIO-DKD Investigators. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol 2021;78:142-52.
75. Tan SY, Cronin H, Byrne S, O’Donovan A, Tuthill A. Appropriateness of aspirin prescribing for primary and secondary prevention of cardiovascular disease in type 2 diabetes in different care settings. Ir J Med Sci 2021; doi: 10.1007/s11845-021-02649-5.
76. Liao EP. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012;125:S1-2.
77. Rana JS, Liu JY, Moffet HH, Sanchez RJ, Khan I, Karter AJ. Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease. Am J Med 2020;133:200-6.
78. Lavie G, Hoshen M, Leibowitz M, et al. Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality. Am J Med 2021;134:643-52.
79. Echouffo-Tcheugui JB, Xu H, Matsouaka RA, et al. Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. Eur Heart J 2018;39:2376-86.
80. Atlas Writing Group, Timmis A, Townsend N, Gale C, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J 2018;39:508-79.
81. Weng J, Zhou Z, Guo L, et al. T1D China Study Group. Incidence of type 1 diabetes in China, 2010-13: population based study. BMJ 2018;360:j5295.
82. Dieleman JL, Squires E, Bui AL, et al. Factors Associated With Increases in US Health Care Spending, 1996-2013. JAMA 2017;318:1668-78.
83. Hu C, Tkebuchava T. Health in All Laws: a better strategy for global health. J Evid Based Med 2022;15:10-4.
84. Hu CS, Tkebuchava T. Structure-Editing: A New Branch? Chin Med J (Engl) 2016; 129:1629-30.
85. Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol 2019;7:179-88.
86. Ruiz HH, López Díez R, Arivazahagan L, Ramasamy R, Schmidt AM. Metabolism, Obesity, and Diabetes Mellitus. Arterioscler Thromb Vasc Biol 2019;39:e166-74.
87. Chung MK, Eckhardt LL, Chen LY, et al; American Heart Association Electrocardiography and Arrhythmias Committee and Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Lifestyle and Cardiometabolic Health. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation 2020;141:e750-72.
88. Rangaswami J, Bhalla V, de Boer IH, et al; American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation 2020;142: e265-86.
89. Filippatos G, Anker SD, Agarwal R, et al; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation 2021;143:540-52.
90. The Lancet. Modernising the NHS: leading the way with diabetes. Lancet 2019;393:200.
91. Hu CS. Analysis of COVID-19 Cases and Public Measures in China. SN Compr Clin Med 2020;2:1306-12.
92. Qian F, Liu G, Hu FB, Bhupathiraju SN, Sun Q. Association Between Plant-Based Dietary Patterns and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA Intern Med 2019;179:1335-44.
93. Owens-Gary MD, Zhang X, Jawanda S, Bullard KM, Allweiss P, Smith BD. The Importance of Addressing Depression and Diabetes Distress in Adults withType 2 Diabetes. J Gen Intern Med 2019;34:320-4.
94. Vergari E, Denwood G, Salehi A, et al. Somatostatin secretion by Na(+)-dependent Ca(2+)-induced Ca(2+) release in pancreatic delta-cells. Nat Metab 2020;2:32-40.
95. De Jesus DF, Zhang Z, Kahraman S, et al. m(6)A mRNA Methylation Regulates Human β-Cell Biology in Physiological States and in Type 2 Diabetes. Nat Metab 2019;1:765-74.
96. Campbell MD, Sathish T, Zimmet PZ, et al. Benefit of lifestyle-based T2DM prevention is influenced by prediabetes phenotype. Nat Rev Endocrino 2020;16: 395-400.
97. Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:545-55.
98. Perreault L, Skyler JS, Rosenstock J. Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:364-77.
99. Caputo V, Termine A, Strafella C, Giardina E, Cascella R. Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes. World J Diabetes 2020;11:155-64.
100. Foran E, Hannigan A, Glynn L. Prevalence of depression in patients with type 2 diabetes mellitus in Irish primary care and the impact of depression on the control of diabetes. Ir J Med Sci 2015;184:319-22.
101. Tudor RM, Garrahy A, Woods CP, et al. The prevalence and incidence of thyroid dysfunction in patients with diabetes - a longitudinal follow-up study. Ir J Med Sci 2020;189:171-5.
102. Manfrini O, Russo V, Ciavarella A, Ceroni L, Montalti M, Fattori R. Coronary plaque quantification and composition in asymptomatic patients with type II diabetes mellitus. J Cardiovasc Med (Hagerstown) 2012;13: 423-31.
103. Stoynev N, Dimova I, Rukova B, et al. Gene expression in peripheral blood of patients with hypertension and patients with type 2 diabetes. J Cardiovasc Med (Hagerstown) 2014;15:702-9.
104. Ruocco G, Evangelista I, Franci B, et al. Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome. J Cardiovasc Med (Hagerstown) 2019;20:81-90.
105. De Luca G, Verdoia M, Savonitto S, et al. Elderly ACS 2 Investigators. Impact of diabetes on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: insights from the ELDERLY ACS 2 trial. J Cardiovasc Med (Hagerstown) 2020;21:453-9.
106. Zwart K, Velthuis S, Polyukhovych YV, et al. Sodium-glucose cotransporter 2 inhibitors: a practical guide for the Dutch cardiologist based on real-world experience. Neth Heart J 2021;29:490-9.
107. Pandey A, Vaduganathan M, Patel KV, et al. Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. JACC Heart Fai 2021;9: 215-23.
108. Echouffo-Tcheugui JB, Zhang S, Florido R, et al. Duration of Diabetes and Incident Heart Failure: The ARIC (Atherosclerosis Risk In Communities) Study. JACC Heart Fail 2021;9:594-603.
109. Brandt-Jacobsen NH, Lav Madsen P, Johansen ML, et al. Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes: Data From the MIRAD Trial. JACC Heart Fail 2021;9:550-8.
110. Pitt B, Filippatos G, Agarwal R, et al. FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63.
111. Hou L, Ge L, Li Y, et al. Physical activity recommendations for patients with type2diabetes: a cross-sectional survey. Acta Diabetol 2020;57:765-77.
112. Phrommintikul A, Wongcharoen W, Kumfu S, et al. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Br J Clin Pharmacol 2019;85:1337-47.
113. Baker DJ, Wilkinson GP, Atkinson AM, et al. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes. Br J Pharmacol 2014;171:1642-54.
114. Shimazawa R, Ikeda M. Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison. Br J Clin Pharmacol 2021;87:3938-48.
115. Levelt E, Pavlides M, Banerjee R, et al. Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes. J Am Coll Cardiol 2016;68: 53-63.
116. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018;72:3200-23.
117. Enquobahrie DA, Dolidze N, Chapidze G, Vadachkoria S, Soh J, Fitzpatrick A, Williams MA. Type 2 diabetes and impaired glucose tolerance among cardiac patients. Acta Cardiol 2007;62:439-44.
118. Canpolat U, Aytemir K, Yorgun H, Hazirolan T, Kaya EB, Ateş AH, Sunman H, Dural M, Yalçin MU, Tokgözoğlu L, Kabakçi G, Oto A. Association of type 2 diabetes mellitus with coronary atherosclerotic plaque burden and morphology measured by multidetector computed tomography coronary angiography. Acta Cardiol 2012;67:71-7.
119. Eren H, Kaya Ü, Öcal L, Öcal AG, Genç Ö, Genç S, Evlice M. Presence of fragmented QRS may be associated with complex ventricular arrhythmias in patients with type-2 diabetes mellitus. Acta Cardiol 2021;76:67-75.
120. Bayramoğlu A, Taşolar H, Kaya Y, et al. Fragmented QRS complexes are associated with left ventricular dysfunction in patients with type-2 diabetes mellitus: a two-dimensional speckle tracking echocardiography study. Acta Cardiol 2018;73:449-56.
121. Wang Q, Fu C, Xia H, Gao Y. Aggravating effect of obstructive sleep apnoea on left ventricular remodelling and function disorder in patients with type 2 diabetes mellitus: a case-control study by 3D speckle tracking echocardiography. Acta Cardiol 2021:1-10.
122. Martens P, Janssens J, Ramaekers J, Dupont M, Mullens W. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Acta Cardiol 2020;75:211-7.
123. Hermans MP, Ahn SA, Rousseau MF. Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelines. Acta Cardiol 2021;76:375-83.
124. Serpytis R, Majauskiene E, Navickas P, et al. Randomized Pilot Trial on Optimal Treatment Strategy, Myocardial Changes, and Prognosis of Patients with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA). Am J Med 2022;135:103-9.
125. Rauh SP, Rutters F, van der Heijden AAWA, et al. External Validation of a Tool Predicting 7-Year Risk of Developing Cardiovascular Disease, Type 2 Diabetes or Chronic Kidney Disease. J Gen Intern Med 2018;33:182-8.
126. Alexander JT, Staab EM, Wan W, et al. Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. J Gen Intern Med 2021; doi: 10.1007/s11606-021-07227-0.
127. Raghavan S, Pachucki MC, Chang Y, et al. Incident Type 2 Diabetes Risk is Influenced by Obesity and Diabetes in Social Contacts: a Social Network Analysis. J Gen Intern Med 2016;31:1127-33.
128. Kobe EA, Lewinski AA, Jeffreys AS, et al. Implementation of an Intensive Telehealth Intervention for Rural Patients with Clinic-Refractory Diabetes. J Gen Intern Med 2022; :1-9. doi: 10.1007/s11606-021-07281-8.
129. Alpert JS. Advances in Science Are Not Linear; They Are Zigzag. Am J Med 2021;S0002-9343(21)00797-X.
130. Anastasiou G, Hatziagelaki E, Liberopoulos E. Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept. J Cardiovasc Pharmacol 2021;78:e12-9.
131. Li W, Chen X, Xie X, et al. Comparison of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists for atrial fibrillation in type 2 diabetes mellitus: systematic review with network meta-analysis of randomised controlled trials. J Cardiovasc Pharmacol 2021; doi: 10.1097/FJC.0000000000001197.
132. Qiu M, Ding LL, Wei XB, Liu SY, Zhou HR. Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis. J Cardiovasc Pharmacol 2021;77:34-7.
133. Vider E, Sapir R, Mosseri E, Gavioli E. Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease. J Cardiovasc Pharmacol 2021; doi: 10.1097/FJC.0000000000001176.
134. Zheng RJ, Wang Y, Tang JN, Duan JY, Yuan MY, Zhang JY. Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol 2021; doi: 10.1097/FJC.0000000000001183.
135. Ye G, Wang S, Peng D. Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol 2021;77:787-95.
136. Wang Z, Guo W, Kuang X, Hou S, Liu H. Nanopreparations for mitochondria targeting drug delivery system: Current strategies and future prospective. Asian J Pharm Sci 2017;12:498-508.
137. Yang L, Yang Y, Chen H, Mei L, Zeng X. Polymeric microneedle-mediated sustained release systems: Design strategies and promising applications for drug delivery. Asian J Pharm Sci 2022;17:70-86.
138. Ng LC, Gupta M. Transdermal drug delivery systems in diabetes management: A review. Asian J Pharm Sci 2020;15:13-25.
139. Liu Y, Zhou S, Gao Y, Zhai Y. Electrospun nanofibers as a wound dressing for treating diabetic foot ulcer. Asian J Pharm Sci 2019;14:130-43.
140. Simos YV, Spyrou K, Patila M, Karouta N, Stamatis H, Gournis D, Dounousi E, Peschos D. Trends of nanotechnology in type 2 diabetes mellitus treatment. Asian J Pharm Sci 2021;16:62-76.